Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Direxion Daily TSLA Bull 2X Shares trades at $12.92. The key difference: Direxion Daily TSLA Bull 2X Shares is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | TSLL | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $23.03 |
52-Week Low | $278.09 | $10.29 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TSLL is trading at $13.09, up 0.54% with a bearish technical signal from moving averages. Key support levels are at $12 and $11, while resistance sits at $13 and $14. The stock shows neutral oscillator readings with RSI levels around 46-50, indicating balanced momentum. Recent news highlights interest in derivative-based ETF strategies and connections to Tesla's performance.
The outlook remains cautious due to bearish technical indicators and limited fundamental data availability. Investment opportunities may exist for those speculating on Tesla-related volatility through this ETF, but risks include market volatility and dependency on underlying asset performance. The neutral sentiment from oscillators suggests waiting for clearer directional signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
